129 related articles for article (PubMed ID: 8174716)
1. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism.
Falsetti L; Pasinetti E
Fertil Steril; 1994 May; 61(5):817-22. PubMed ID: 8174716
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism.
Falsetti L; Pasinetti E; Ceruti D
Acta Eur Fertil; 1994; 25(5):303-6. PubMed ID: 7660719
[TBL] [Abstract][Full Text] [Related]
3. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease.
Ciotta L; Cianci A; Giuffrida G; Marletta E; Aglianò A; Palumbo G
Fertil Steril; 1996 Jan; 65(1):61-7. PubMed ID: 8557156
[TBL] [Abstract][Full Text] [Related]
4. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
Elkind-Hirsch KE; Anania C; Mack M; Malinak R
Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
[TBL] [Abstract][Full Text] [Related]
5. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
6. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
De Leo V; Fulghesu AM; la Marca A; Morgante G; Pasqui L; Talluri B; Torricelli M; Caruso A
Gynecol Endocrinol; 2000 Dec; 14(6):411-6. PubMed ID: 11228061
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
Castelo-Branco C; Martínez de Osaba MJ; Pons F; Fortuny A
Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
[TBL] [Abstract][Full Text] [Related]
9. Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome.
Battaglia C; Genazzani AD; Artini PG; Salvatori M; Giulini S; Volpe A
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):180-7. PubMed ID: 9793190
[TBL] [Abstract][Full Text] [Related]
10. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome.
Genazzani AD; Petraglia F; Battaglia C; Gamba O; Volpe A; Genazzani AR
Fertil Steril; 1997 Mar; 67(3):463-8. PubMed ID: 9091331
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
12. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.
Azziz R; Ochoa TM; Bradley EL; Potter HD; Boots LR
J Clin Endocrinol Metab; 1995 Dec; 80(12):3406-11. PubMed ID: 8530573
[TBL] [Abstract][Full Text] [Related]
13. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
Acién P; Mauri M; Gutierrez M
Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
Bayhan G; Bahçeci M; Demirkol T; Ertem M; Yalinkaya A; Erden AC
Clin Exp Obstet Gynecol; 2000; 27(3-4):203-6. PubMed ID: 11214952
[TBL] [Abstract][Full Text] [Related]
15. An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism.
Vegetti W; Testa G; Maggioni P; Motta T; Falsetti L; Crosignani PG
Gynecol Obstet Invest; 1996; 41(4):260-8. PubMed ID: 8793497
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy.
Morcos RN; Abdul-Malak ME; Shikora E
Fertil Steril; 1994 Mar; 61(3):427-31. PubMed ID: 8137961
[TBL] [Abstract][Full Text] [Related]
18. Endocrinology Update: Hirsutism.
Heidelbaugh JJ
FP Essent; 2016 Dec; 451():17-24. PubMed ID: 27936531
[TBL] [Abstract][Full Text] [Related]
19. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
20. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome.
Prelević GM; Puzigaća Z; Balint-Perić LA
Ann N Y Acad Sci; 1993 May; 687():255-62. PubMed ID: 8323181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
